Botulinum toxin and gastrointestinal tract disorders: Panacea, placebo, or pathway to the future?

Gastroenterology and Hepatology

Volumn 4, Issue 4, 2008, Pages 283-295

  Lacy, Brian E ^a,b   Weiser, Kirsten ^a,b   Kennedy, Abigail ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Achalasia; Anal fissure; Botulinum toxin; Esophagus; Gastroparesis; Obesity; Sphincter of Oddi

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; GLYCERYL TRINITRATE; METOCLOPRAMIDE; PLACEBO;

ANUS FISSURE; ARTICLE; BOTULISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; ESOPHAGUS ACHALASIA; ESOPHAGUS SPASM; GASTROINTESTINAL DISEASE; HEMORRHOID; HEMORRHOIDECTOMY; HUMAN; OBESITY; PROCTALGIA; STOMACH PARESIS; UNSPECIFIED SIDE EFFECT; VATER PAPILLA STENOSIS;

EID: 43249094935     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Opthalmol. 1973;12:924-927.
2. Pasricha PJ, Ravich WJ, Kalloo KN. Effects of intrasphincteric botulinum toxin on the lower esophageal sphincter in piglets. Gastroenterology. 1993;105:1045-1049.
3. Cherington M. Botulism: update and review. Semin Neurol. 2004;24:155-163.
4. Kerner J. Neue Beobachtungen uber die in Wurttemberg so haufig vorfallenden todlichen Vergiftungen durch den Genuss geraucherter Wurste. Osiander, Tubingen. 1820.
5. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison." Neurology. 1999;53:1850-1853.
6. van Ermengem E. Ueber einen neuen anaeroben Bacillus und seize Beziehungen zum Botulismus. Z Hygiene Infektionskrankheiten. 1897;26:1-56.
7. Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm. 2007 Apr 26 [Epub ahead of print].
8. Scott AB. Botulinum toxin injection to correction strabismus. Trans Am Ophthalmol Soc. 1979;79:924-927.
9. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059-1070.
10. Clinical Pharmacology [database online]. Tampa, Fla: Gold Standard, Inc.; 2007. Available at: http://www.clinicalpharmacology.com. Updated November 2007.
11. Brunton LL, ed. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, New York: McGraw-Hill; 2006.
12. Physicians' Desk Reference. 61st ed. Montvale, NJ: Thomson PDR; 2007.
13. Hamdy RC, Montpetit K, Ruck-Gibis J, Thorstad K, Raney E, et al. Safety and efficacy of botox injection in alleviating post-operative pain and improving quality of life in lower extremity limb lengthening and deformity correction. Trials. 2007;8:27.
14. Ma J, Shen J, Lee CA, Elsaidi GA, Smith TL, et al. Gene expression of nAChR, SNAP-25 and GAP-43 in skeletal muscles following botulinum toxin A injection: a study in rats. J Orthopaedic Res. 2005;23:302-309.
15. Bambrick L, Gordon T. Acetylcholine receptors and sodium channels in denervated and botulinum-toxin-treated adult rat muscle. J Physiol. 1987;382:69-86.
16. Tagerud S, Libelius R, Thesleff S. Effects of botulinum toxin induced muscle paralysis on endocytosis and lysosomal enzyme activities in mouse skeletal muscle. Pflugers Arch. 1986;407:275-278.
17. Thesleff S, Molgó J, Tågerud S. Trophic interrelations at the neuromuscular junction as revealed by the use of botulinal neurotoxins. J Physiol. 1990;84:167-173.
18. Neubrand M, Scheurlen C, Schepke M, Sauerbruch T. Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy. 2002;34:519-523.
19. Dodd SL, Selsby J, Payne A, Judge A, Dott C. Botulinum neurotoxin type A causes shifts in myosin heavy chain composition in muscle. Toxicon. 2005;46:196-203.
20. Shen J, Ma J, Lee C, Smith BP, Smith TL, et al. How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: study in juvenile rats. J Orthopaedic Res. 2006;24:1128-1135.
21. Zanitotto G, Annese V, Costantini M, Del Genio A, Costantino M, et al. Randomized controlled trial of botulinum toxin versus laparoscopic Heller myotomy for esophageal achalasia. Ann Surg. 2004;239:364-370.
22. Duchen LW, Strich SJ. The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse. Q J Exp Physiol Cogn Med Sci. 1968;53:84-89.
23. Foran PG, Davletov B, Meunier FA. Getting muscles moving again after botulinum toxin: novel therapeutic challenges. Trends Mol Med. 2003;9:291-299.
24. Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN. Intrasphincteric botulinum toxin for the treatment of achalasia. New Engl J Med. 1995;332:774-778.
25. Leyden JE, Moss AC, MacMathuna P. Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Cochrane Database Syst Rev. 2006;(4):CD005046.
26. Bassotti G, D'Onofrio V, Battaglia E, Fiorella S, Dughera L, et al. Treatment with botulinum toxin of octo-nonagerians with oesophageal achalasia: a two-year follow-up study. Aliment Pharmacol Ther. 2006;23:1615-1619.
27. Dughera L, Battaglia E, Maggio D, Cassolino P, Mioli PR, et al. Botulinum toxin treatment of oesophageal achalasia in the old old and oldest old: a 1-year follow-up study. Drugs Aging. 2005;22:779-783.
28. Spechler SJ. American Gastroenterological Association medical position statement on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology. 1999;117:229-232.
29. Pasricha PJ, Rai R, Ravich WJ, Hendrix TR, Kalloo AN. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology. 1996;110:1410-1415.
30. Richardson WS, Willis GW, Smith JW. Evaluation of scar formation after botulinum toxin injection or forced balloon dilation to the lower esophageal sphincter. Surg Endosc. 2003;17:696-698.
31. Bloomston M, Fraiji E, Boyce HW Jr, Gonzalvo A, Johnson M, Rosemurgy AS. Preoperative intervention does not affect esophageal muscle histology or patient outcomes in patients undergoing laparoscopic Heller myotomy. J Gastrointest Surg. 2003;7:181-188.
32. Cowgill SM, Villadolid DV, Al-Saadi S, Rosemurgy AS. Difficult myotomy is not determined by preoperative therapy and does not impact outcome. JSLS. 2007;11:336-343.
33. Chiu MJ, Chang YC, Hsiao TY. Prolonged effect of botulinum toxin injection in the treatment of cricopharyngeal dysphagia: a case report and literatute review. Dysphagia. 2004;19:52-57.
34. Moerman MB. Cricopharyngeal botox injection: indications and technique. Curr Opin Otolaryngol Head Neck Surg. 2006;14:431-436.
35. Lacy BE, Zayat EN, Crowell MD. Botulinum toxin in hypertensive lower esophageal sphincter: a manometric case study. Dysphagia. 2002;17:75-80.
36. Miller LS, Pullela SV, Parkman HP, Schiano TD, Cassidy MJ, et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol. 2002;97:1640-1646.
37. Storr M, Allescher HD, Rösch T, Born P, Weigert N, Classen M. Treatment of symptomatic diffuse esophageal spasm by endoscopic injection of botulinum toxin: a prospective study with long-term follow-up. Gastrointest Endosc. 2001;54:754-759.
38. Lacy BE, Crowell MD, Koch KL. Gastric motility. In: Schuster MM, Crowell MD, Koch KL, eds. Schuster Atlas of Gastrointestinal Motility. 2nd ed. Hamilton: BC Decker; 2002:135-150.
39. Alleschet HD, Daniel EE, Dent J, Fox JE, Kostolanska F. Extrinsic and intrinsic neural control of pyloric sphincter pressure in the dog. J Physiol. 1988;401:17-38.
40. Edin R. The vagal control of the pylotic motor function: a physiological and immunohistochemical study in cat and man. Acta Physiol Scand Suppl. 1980;485:1-30.
41. Milenov K, Golenhofen K. Differentiated contractile responses of gastric smooth muscle to substance P. Pflugers Arch. 1983;397:29-34.
42. Allescher HD, Daniel EE, Dent J, Fox JE. Inhibitory function of VIP-PHI and galanin in canine pylorus. Am J Physiol. 1989;256:G789-797.
43. Allescher HD, Ahmad S, Kostolanska F, Kwan CY, Daniel EE. Modulation of pyloric motor activity via adrenergic receptors. J Pharmacol Exp Ther. 1989;249:652-659.
44. Tomita R, Tanjoh K, Fujisaka S, Fukuzawa M. The role of nitric oxide (NO) in the human pyloric sphincter. Hepatogastroenterology. 1999;46:2999-3003.
45. Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986;90:1919-1925.
46. Lacy BE, Crowell MD, Schettler-Duncan A, Mathis C, Pasricha PJ. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus. Diabetes Care. 2004;27:2341-2347.
47. Fraser R, Horowitz M, Dent J. Hyperglycemia stimulates pyloric motility in normal subjects. Gut. 1991;32:475-478.
48. James AN, Ryan JP, Parkman HP. Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2003;285:G291-G297.
49. Hou YP, Zhang YP, Song YF, Zhu CM, Wang YC, Xie GL. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo. Can J Physiol Pharmacol. 2007;85:209-214.
50. Wiesel PH, Schneider R, Dorta G, Blum AL, Gillet M, Michetti P. Botulinum toxin for refractory postoperative pyloric spasm. Endoscopy. 1997;29:132.
51. Gupta P, Rao SSC. Attenuation of isolated pyloric pressure waves in gastroparesis in response to botulinum toxin injection: a case report. Gastrointest Endosc. 2002;56:770-772.
52. Parkman HP, Hasler WL, Fisher RS. American Gastroenterology Association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127: 1589-1591.
53. Lacy BE, Weiser K. Gastric motility, gastroparesis, and gastric stimulation. Surg Clin North Am. 2005;85:967-987.
54. Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion. 1999;60:422-427.
55. Orihata M, Sarna SK. Contractile mechanisms of action of gastroprokinetic agents: cisapride, metoclopramide, and domperidone. Am J Physiol. 1994;266:G665-676.
56. Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc. 2002;55:920-923.
57. Bromer MQ, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc. 2005;61:833-839.
58. Miller LS, Szych GA, Kantot SB, Bromer MQ, Knight LC, et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphinc-ter muscle. Am J Gastroenterol. 2002;97:1653-1660.
59. Arts J, Van Gool S, Caenepeel P, Verbeke K, Janssens J, Tack J. Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients. Aliment Pharmacol Ther. 2006;24:661-667.
60. Arts J, Holvoet L, Caenepeel P, Bisschops R, Sifrim D, et al. Clinical trial: a randomized-controlled crossover study of intra-pyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26:1251-1258.
61. Revicki D, Rentz A, Dubois D, Kahrilas P, Stanghellini V, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther. 2003;18:141-350.
62. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103:416-423.
63. Maria G, Cassetta E, Gui D, Brisinda G, Bennvoglio AR, Albanese A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med. 1998;338:217-220.
64. Brisinda G, Cadeddu F, Brandara F, Marniga G, Maria G. Randomized clinical trial comparing botulinum toxin injections with 0.2 percent nitroglycerin ointment for chronic anal fissures. Br J Surg. 2007;94:162-167.
65. Witte ME, Klasse JM. Botulinum toxin Z injection in ISDN ointment-resistant chronic anal fissures. Dig Surg. 2007;24:197-201.
66. Gui D, Rossi S, Runfola M, Magalini SC. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment Pharmacol Ther. 2003;18:1-16.
67. Jost WH, Schrank B. Repeat botulinum toxin injections in anal fissure: in patients with relapse and after insufficient effect of first treatment. Dig Dis Sci. 1999;44:1588-1589.
68. Nelson R. Non surgical therapy for anal fissure. Cochrane Database Syst Rev. 2003;(4):CD003431.
69. Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Albanese A. Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. Dis Colon Rectum. 2000;43:376-380.
70. Maria G, Cadeddu F, Brandara F, Marniga G, Brisinda G. Experience with type A botulinum toxin for treatment of outlet-type constipation. Am J Gastroenterol. 2006;101:2570-2575.
71. Cadeddu F, Bentivioglio AR, Brandara F, Marniga G, Brisinda G, Maria G. Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment. Aliment Pharmacol Ther. 2005;22:997-1003.
72. Maria G, Brisinda G, Bentivoglio AR, Albanese A, Sganga G, Castagneto M. Antetior rectocele due to obstructed defecation relieved by botulinum toxin. Surgery. 2001;129:524-529.
73. Ho YH, Tan M. Ambulatory anorectal manometric findings in patients before and after hemorrhoidectomy. Int J Colorectal Dis. 1998;12:296-297.
74. Parti R, Almasio PL, Muggeo VM, Buscemi S, Arcara M, et al. Improvement of wound healing after hemorrhoidectomy: a double-blind, randomized study of botulinum toxin injection. Dis Colon Rectum. 2005;48:2173-2179.
75. Bistritz L, Bain VG. Sphincter of Oddi dysfunction: managing the patient with chronic biliary pain. World J Gastroenterol. 2006;12:3793-3802.
76. Wehrmann T, Seifert H, Seipp M, Lembcke B, Caspary WF. Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction. Endoscopy. 1998;30:702-707.
77. Wehrmann T, Schmitt TH, Arndt A, Lembcke B, Caspary WF, Seifert H. Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction. Aliment Pharmacol Ther. 2000;14:1469-1477.
78. Gorelick A, Barnett J, Chey W, Anderson M, Elta G. Botulinum toxin injection after biliary sphincterotomy. Endoscopy. 2004;36:170-173.
79. Pasricha PJ, Miskovsky EP, Kalloo AN. Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction. Gut. 1994;35:1319-1321.
80. Gui D, De Gaetano A, Spada PL, Viggiano A, Cassetta E, Albanese A. Botulinum toxin injected in the gastric wall reduces body weight and food intake in rats. Aliment Pharmacol Ther. 2000;14:829-834.
81. Albani G, Petroni ML, Mauro A, Liuzzi A, Lezzi G, et al. Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. J Gastroenterol. 2005;40:833-835.
82. Foschi D, Corsi F, Lazzaroni M, Sangaletti O, Riva P, et al. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes (Lond). 2007;31:707-712.
83. Garcia-Compean D, Mendoza-Fuerte E, Martinez JA, Villarreal I, Maldonado H. Endoscopic injection of botulinum toxin in the gastric antrum for the treatment of obesity. Results of a pilot study. Gastroenterol Clin Biol. 2005;29:789-791.
84. Junior AC, Savassi-Rocha PR, Coelho LG, Sposito MM, Albuquerque W, et al. Botulinum A toxin injected into the gastric wall for the treatment of class III obesity: a pilot study. Obes Surg. 2006;16:335-343.
85. Gui D, Mingrone G, Valenza V, Spada PL, Mutignani M, et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther. 2006;23:675-680.
86. Mittermair R, Keller C, Geibel J. Intragastric injection of botulinum toxin A for the treatment of obesity. Obes Surg. 2007;17:732-736.